The default mode network integrity in patients with Parkinson's disease is levodopa equivalent dose-dependent
Jazyk angličtina Země Rakousko Médium print-electronic
Typ dokumentu časopisecké články
- MeSH
- antiparkinsonika terapeutické užití MeSH
- dospělí MeSH
- kognitivní poruchy * farmakoterapie etiologie patologie MeSH
- kyslík krev MeSH
- levodopa terapeutické užití MeSH
- lidé středního věku MeSH
- lidé MeSH
- magnetická rezonanční tomografie MeSH
- mozek krevní zásobení účinky léků MeSH
- neuropsychologické testy MeSH
- Parkinsonova nemoc * komplikace farmakoterapie patologie MeSH
- počítačové zpracování obrazu MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- světelná stimulace MeSH
- vztah mezi dávkou a účinkem léčiva MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- Názvy látek
- antiparkinsonika MeSH
- kyslík MeSH
- levodopa MeSH
Disturbances in the default mode network (DMN) have been described in many neurological and psychiatric disorders including Parkinson's disease (PD). The DMN is characterized by basal activity that increases during rest or passive visual fixation and decreases ("deactivates") during cognitive tasks. The network is believed to be involved in cognitive processes. We examined the DMN in PD patients on dopaminergic medication with normal cognitive performance compared to age- and gender-matched healthy controls (HC) using fMRI and three methodological procedures: independent component analysis of resting-state data, analysis of deactivation during a complex visual scene-encoding task, and seed-based functional connectivity analysis. In the PD group, we also studied the effect of dopaminergic medication on the DMN integrity. We did not find any difference between the PD and HC groups in the DMN, but using the daily levodopa equivalent dose as a covariate, we observed an enhanced functional connectivity of the DMN in the posterior cingulate cortex and decreased activation in the left parahippocampal gyrus during the cognitive task. We conclude that dopaminergic therapy has a specific effect on both the DMN integrity and task-related brain activations in cognitively unimpaired PD patients, and these effects seem to be dose-dependent.
Zobrazit více v PubMed
Neurology. 2000 Dec 12;55(11):1613-20 PubMed
Neuroimage. 2009 Oct 1;47(4):1408-16 PubMed
Neurology. 1980 Dec;30(12):1326-30 PubMed
Am J Psychiatry. 2007 Mar;164(3):450-7 PubMed
Radiology. 2002 Oct;225(1):253-9 PubMed
Neurosci Biobehav Rev. 2009 Mar;33(3):279-96 PubMed
Neurosci Lett. 1989 Feb 27;97(3):266-70 PubMed
Eur J Neurosci. 2010 Aug;32(4):598-605 PubMed
Magn Reson Med. 2000 Jan;43(1):45-51 PubMed
Proc Natl Acad Sci U S A. 2004 Mar 30;101(13):4637-42 PubMed
Neurology. 2005 Aug 9;65(3):404-11 PubMed
Mov Disord. 2002 Jul;17(4):682-92 PubMed
Neurosci Lett. 2008 Dec 5;447(1):12-6 PubMed
Magn Reson Imaging. 2007 Dec;25(10):1347-57 PubMed
Eur J Neurosci. 2004 Nov;20(9):2441-6 PubMed
Hum Brain Mapp. 2010 Jan;31(1):88-97 PubMed
Hum Brain Mapp. 2007 Nov;28(11):1251-66 PubMed
Eur Neuropsychopharmacol. 2010 Nov;20(11):784-92 PubMed
J Neurosci. 2005 Aug 24;25(34):7709-17 PubMed
J Neurosci. 2008 Oct 15;28(42):10687-95 PubMed
Neuroimage. 2007 Oct 1;37(4):1083-90; discussion 1097-9 PubMed
J Cogn Neurosci. 1999 Jan;11(1):80-95 PubMed
BMC Neurosci. 2009 Nov 23;10:137 PubMed
Schizophr Bull. 2007 Jul;33(4):1004-12 PubMed
Neuroreport. 2006 Feb 6;17(2):209-13 PubMed
J Neurosci. 2009 Feb 4;29(5):1538-43 PubMed
Nat Rev Neurosci. 2001 Oct;2(10):685-94 PubMed
Cereb Cortex. 2010 May;20(5):1175-86 PubMed
Trends Cogn Sci. 2010 Oct;14(10):464-72 PubMed
Proc Natl Acad Sci U S A. 2001 Jan 16;98(2):676-82 PubMed
PLoS One. 2009 Jun 30;4(6):e6102 PubMed
Proc Natl Acad Sci U S A. 2005 Jul 5;102(27):9673-8 PubMed
J Neurol Neurosurg Psychiatry. 1992 Mar;55(3):181-4 PubMed
Neuropsychologia. 2008;46(6):1648-56 PubMed
Neurosci Lett. 2007 May 7;417(3):297-302 PubMed
Brain. 2008 Aug;131(Pt 8):2094-105 PubMed
Brain Dev. 2007 Mar;29(2):83-91 PubMed
J Neurosci. 2008 Apr 2;28(14):3697-706 PubMed
J Neurosci. 2010 Feb 10;30(6):2356-64 PubMed
Ann Neurol. 2002 Feb;51(2):156-64 PubMed
PLoS Comput Biol. 2007 Feb 2;3(2):e17 PubMed
Arch Neurol. 2009 Jul;66(7):877-83 PubMed
Nat Rev Neurosci. 2007 Sep;8(9):700-11 PubMed
Hum Brain Mapp. 2001 Nov;14(3):140-51 PubMed
J Cogn Neurosci. 2010 Jun;22(6):1112-23 PubMed
J Neurosci. 2009 Jun 3;29(22):7364-78 PubMed
Neurosci Biobehav Rev. 2006;30(1):1-23 PubMed
PLoS Comput Biol. 2008 Jun 27;4(6):e1000100 PubMed
Brain. 2004 Oct;127(Pt 10):2286-98 PubMed
Neuroimage. 2006 Jun;31(2):496-504 PubMed
J Comp Neurol. 1988 Jul 1;273(1):99-119 PubMed
Neurosci Lett. 2009 Jul 10;458(1):1-5 PubMed
Schizophr Res. 2008 Mar;100(1-3):120-32 PubMed
Grey matter changes in cognitively impaired Parkinson's disease patients
